First Time Loading...

Instem PLC
LSE:INS

Watchlist Manager
Instem PLC Logo
Instem PLC
LSE:INS
Watchlist
Price: 830 GBX
Updated: Mar 29, 2024

Intrinsic Value

Instem Plc engages in the provision of information technology solutions and services to the global health and life sciences community. [ Read More ]

The intrinsic value of one INS stock under the Base Case scenario is 944.91 GBX. Compared to the current market price of 830 GBX, Instem PLC is Undervalued by 12%.

Key Points:
INS Intrinsic Value
Base Case
944.91 GBX
Undervaluation 12%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Instem PLC

Backtest INS Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling INS stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials

Balance Sheet Decomposition
Instem PLC

Current Assets 24.2m
Cash & Short-Term Investments 8.4m
Receivables 15.4m
Other Current Assets 322k
Non-Current Assets 59.5m
PP&E 1.5m
Intangibles 58m
Other Non-Current Assets 14k
Current Liabilities 25.5m
Accounts Payable 4.6m
Short-Term Debt 1m
Other Current Liabilities 19.9m
Non-Current Liabilities 3.5m
Long-Term Debt 322k
Other Non-Current Liabilities 3.2m
Efficiency

Earnings Waterfall
Instem PLC

Revenue
60.4m GBP
Operating Expenses
-54.1m GBP
Operating Income
6.3m GBP
Other Expenses
-2.9m GBP
Net Income
3.4m GBP

Free Cash Flow Analysis
Instem PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

INS Profitability Score
Profitability Due Diligence

Instem PLC's profitability score is 50/100. The higher the profitability score, the more profitable the company is.

Positive Free Cash Flow
Positive Revenue Growth Forecast
Positive 1-Year Revenue Growth
Positive Operating Income
50/100
Profitability
Score

Instem PLC's profitability score is 50/100. The higher the profitability score, the more profitable the company is.

INS Solvency Score
Solvency Due Diligence

Instem PLC's solvency score is 86/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
Negative Net Debt
Low D/E
High Altman Z-Score
86/100
Solvency
Score

Instem PLC's solvency score is 86/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

INS Price Targets Summary
Instem PLC

Wall Street analysts forecast INS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for INS is 1 023 GBX .

Lowest
Price Target
Not Available
Average
Price Target
1 023 GBX
23% Upside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

INS Price
Instem PLC

1M 1M
-
6M 6M
0%
1Y 1Y
+32%
3Y 3Y
+31%
5Y 5Y
+171%
10Y 10Y
+323%
Annual Price Range
830
52w Low
590
52w High
832.5
Price Metrics
Average Annual Return 44.66%
Standard Deviation of Annual Returns 27.58%
Max Drawdown -37%
Shares Statistics
Market Capitalization 190m GBX
Shares Outstanding 24 053 400
Percentage of Shares Shorted
N/A

INS Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Instem PLC Logo
Instem PLC

Country

United Kingdom

Industry

Health Care

Market Cap

190m GBP

Dividend Yield

0%

Description

Instem Plc engages in the provision of information technology solutions and services to the global health and life sciences community. The company is headquartered in Stone, Staffordshire and currently employs 304 full-time employees. The company went IPO on 2010-10-13. The firm operates through four segments: Study Management, Regulatory Solutions, In Silico Solutions and Clinical Trials Acceleration. Its Study Management Solutions is a software that enables organizations to collect, review, manage and report discovery and preclinical report. Its Regulatory Solutions is a software, outsourced services and consultancy for managing, storing, sharing, submitting and maintaining information compliant with agency regulations. The firm's In Silico Solutions enables researchers to generate scientific insights through identification, extraction and analysis of information. Its Clinical Trials Acceleration Solutions is a technology solution and consulting service to facilitate data integration, statistics, analytics and insights for companies any size or stage of clinical trial analysis.

Contact

STAFFORDSHIRE
Stone
Diamond Way, Stone Business Park
+441785825600.0
http://www.instem.com/

IPO

2010-10-13

Employees

304

Officers

CEO & Exec. Director
Mr. Phil J. Reason
CFO, Sec. & Exec. Director
Mr. Nigel John Goldsmith
Chief Operating Officer
Ms. Marybeth Thompson
Chief Scientific Officer
Dr. Gordon Smith Baxter
VP of Governance, Risk Management & Compliance
Mr. Vince D'Angelo
VP of Global Marketing
Mr. Gary Mitchell
Show More
VP of Corp. Devel.
Mr. Adrian Gare
Head of People Services
Ms. Eve Leconte
Exec. VP of Regulatory eStudy Solutions
Mr. Mike Harwood
Exec. VP of Preclinical Solutions
Mr. Gregor Grant
Show Less

See Also

Discover More
What is the Intrinsic Value of one INS stock?

The intrinsic value of one INS stock under the Base Case scenario is 944.91 GBX.

Is INS stock undervalued or overvalued?

Compared to the current market price of 830 GBX, Instem PLC is Undervalued by 12%.